Clinical Report: Impact of Pegylated Interferon α-2b on LDL Levels in CHB Patients
Overview
This study investigates the effects of pegylated interferon α-2b on low-density lipoprotein (LDL) levels in chronic hepatitis B (CHB) patients. Results indicate significant reductions in LDL levels in patients receiving Peg-IFNα-2b monotherapy compared to those on nucleos(t)ide analogs alone.
Background
Chronic hepatitis B (CHB) affects millions globally and poses significant health risks, including liver disease and increased cardiovascular risk. Antiviral therapies, particularly pegylated interferon α-2b (Peg-IFNα-2b), are crucial in managing CHB, yet their impact on lipid metabolism, specifically LDL levels, remains unclear.
Data Highlights
Group
LDL Change (mmol/L)
Peg-IFNα-2b Monotherapy
-0.3 to -0.4
NAs + Peg-IFNα-2b
Intermediate Reduction
NAs Monotherapy
No Significant Change
Key Findings
Peg-IFNα-2b monotherapy resulted in a significant decrease in LDL levels after 48 weeks.
Combination therapy with NAs and Peg-IFNα-2b showed an intermediate reduction in LDL levels.
No significant change in LDL levels was observed in the NAs monotherapy group.
LDL level reductions were consistent across various subgroups including age, gender, and fatty liver status.
Statistical significance was maintained after adjusting for key confounders (P < 0.05).
Clinical Implications
The findings suggest that Peg-IFNα-2b may have a beneficial effect on LDL levels in CHB patients, which could have implications for cardiovascular health. Clinicians should consider monitoring lipid profiles in patients undergoing Peg-IFNα-2b therapy.
Conclusion
Peg-IFNα-2b treatment is associated with a significant reduction in LDL levels in CHB patients.
